在发布业绩公告的当日，爱美客也发布了2023年第一期限制性股票激励计划首次授予部分符合归属条件的公告。据公告，本次符合归属条件的激励对象人数122人，限制性股票拟归属数量16.0787万股，限制性股票授予价格197.48元/股。In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.
In Q3, imeik technology development's revenue increased by 1.10% year-on-year, and net income increased by 2.13% year-on-year. The company's operational scale is steadily improving, and its profitability meets market expectations.
On Wednesday, the 23rd, imeik technology development released the 2024 third-quarter report.
- Revenue: In the third quarter, revenue reached approximately 0.719 billion yuan, a year-on-year increase of 1.10%; in the first three quarters, revenue reached approximately 2.376 billion yuan, a year-on-year increase of 9.46%.
- Net Income: In the third quarter, net income was approximately 0.465 billion yuan, an increase of 2.13% year-on-year; in the first three quarters, net income was approximately 1.586 billion yuan, an increase of 11.79% year-on-year.
- Basic earnings per share were 1.54 yuan/share, a decrease of 26.56% year-on-year.
On the day of announcing the performance report, imeik technology development also announced the first issuance of restricted stock incentive plan for 2023 to certain qualified recipients. According to the announcement, this incentive targets 122 eligible individuals, with a planned allocation of 0.160787 million shares of restricted stock at a grant price of 197.48 yuan per share.
IMEIK Technology Development's products are mainly used in the medical beauty industry, covering a variety of core products such as gel, solution, and collagen. In the future, it will gradually expand to categories such as optoelectronic equipment, botulinum toxin, and simuagrulide, making the product matrix increasingly perfect.
During the reporting period, IMEIK Technology Development's good news on new products and research and development progress has been frequently reported and highly anticipated by the market. On October 9, the company's product "Cross-linked hyaluronic acid sodium gel containing polyvinyl alcohol gel microspheres for medical use" obtained the "Medical Device Registration Certificate" issued by the National Medical Products Administration.
On October 14, IMEIK Technology Development's wholly-owned subsidiary, Peking Nobotech Biotechnology Co., Ltd., received the "Drug Clinical Trial Approval Notification" approved and issued by the National Medical Products Administration for simuagrulide, and will conduct Phase III clinical trials in the near future.
In addition, IMEIK Technology Development has completed the capital increase of and acquired the controlling stake in Emec Innovations Medical Technology (Zhuhai) Co., Ltd. Within the year, Emec Innovations owns products such as the "Hi Blast Water" hydro Oxygen gun and disposable sterile injection needles, expanding the company's layout in the medical beauty equipment field, further enriching the company's product matrix, and enhancing the company's competitiveness and innovation capabilities in the medical beauty industry.
